Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05436561 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 1, 2025 to Dec 1, 2026
    • Study completion date: Dec 1, 2025 to Jun 30, 2027
    v6
  2. Primary completion date: Jun 1, 2024 to Jun 1, 2025
    • Study completion date: Jan 1, 2025 to Dec 1, 2025
    v5
  3. Enrollment target: 50 to 61v4
  4. Start date: Jan 1, 2021 to Jun 1, 2022v3 Show 4 more changesShow less
    • Primary completion date: Jan 1, 2024 to Jun 1, 2024
    • Eligibility criteria revised
    • Study description shortened, about 1 word
    • Study title shortened, about 1 word
  5. Secondary endpoints revised (4)
    • Study description expanded, about 1 word
    • Study title shortened, about 4 words
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan (100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML \>=55 years.
Trial Details
NCT Number NCT05436561
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Conditions
(from sponsor)		 Disease-free Survival
Enrollment 61 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov